This combination therapy of anti-TCR with anti-TNF-α is a viable option especially in the LADA (latent autoimmune diabetes in adults) form of autoimmune diabetes in view of the slower disease progression both in LADA patients and in a rat model of human LADA than in patients and in the IDDM rat model with early manifesting T1D [36, 40, 45–48]. The gene discussed is TNF; the disease is type 1 diabetes mellitus.